Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [7][18]. Core Views - The company's performance in 2024 met expectations, with a revenue of 3.924 billion yuan, a slight decrease of 0.20% year-on-year, and a net profit of 826 million yuan, a significant increase of 536.09% year-on-year [2][4]. - In Q1 2025, the company experienced a revenue decline of 11.85% year-on-year, totaling 885 million yuan, and a net profit decrease of 52.19%, amounting to 85 million yuan [2][4]. - The report emphasizes that short-term fluctuations do not alter the company's long-term growth potential, particularly as it positions itself as a unique overseas formulation commercialization platform [4][5]. Financial Performance Summary - For 2024, the company achieved a revenue of 39.24 billion yuan and a net profit of 8.26 billion yuan, with Q4 showing a revenue increase of 5.84% year-on-year [4][5]. - The report highlights a significant decline in revenue from the heparin raw material segment, down 51.61% year-on-year, while the formulation business grew by 18.30% [4][5]. - The company is expected to see net profits of 1.063 billion yuan in 2025, with growth rates of 29%, 33%, and 30% projected for the following years [5][6]. Market Opportunities - The global biosimilar market is anticipated to grow rapidly as key biological drug patents expire, presenting significant opportunities for the company [5]. - The company has made strategic acquisitions and partnerships, including the full asset acquisition of Coherus BioSciences' adalimumab biosimilar, which has already generated over 70 million yuan in sales since its launch [5][6]. - The upcoming approval of liraglutide in April 2025 is expected to convert prior investments into substantial revenue growth [4][5].

公司近一年市场表现 | 年 市场数据：2025 | 月 5 | 日 23 | | | --- | --- | --- | --- | | 收盘价（元）： | | | 71.75 | | 总股本（亿股）： | | | 2.62 | | 流通股本（亿股）： | | | 2.62 | | 流通市值（亿元）： | | | 187.74 | | 基础数据：2025 年 3 月 | 31 日 | | | --- | --- | --- | | 每股净资产（元）： | | 16.15 | | 每股资本公积（元）： | | 7.75 | | 每股未分配利润（元）： | | 7.17 | | 资料来源：最闻 | | | 通信终端及配件 移远通信（603236.SH） 增持-A(维持) 2025 年 5 月 26 日 公司研究/公司快报 事件描述： 公司发布 2024 年年报和 2025 一季度报告。2024 年，公司实现营收 185.94 亿元，同比+34.14%；实现归母净利润 5.88 亿元，同比+548.49%。2025Q1， 公司实现营收 52.21 亿元，同比+32.05%；实现归母净利润 2.12 亿元，同比 +2 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company focuses on three core businesses: "Perception, Connection, and Intelligent Manufacturing," targeting the new energy vehicle and digital empowerment sectors. It aims to innovate continuously based on customer needs and integrate into national strategies and industry developments [4]. - For 2024, the company is projected to achieve revenue of 11.709 billion yuan, a year-on-year increase of 13.57%, and a net profit attributable to shareholders of 1.221 billion yuan, up 21.17% year-on-year. The growth is driven by the demand for intelligent manufacturing and connection services, particularly in the AIGC application field [4][5]. - The company maintains a global leadership position in thermal management for new energy vehicles and multifunctional sensor technology, with significant revenue contributions from its sensor business [4]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 16.275 billion yuan, 20.012 billion yuan, and 23.577 billion yuan, respectively. Corresponding net profits are expected to be 1.701 billion yuan, 2.179 billion yuan, and 2.716 billion yuan [9][11]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 25 times for 2025, 19 times for 2026, and 16 times for 2027 [9]. Business Developments - The company plans to establish a joint venture with Lika Precision to enhance its capabilities in 3D printing, focusing on SLM manufacturing technology for various applications [6][8]. - The connection business is experiencing explosive growth, particularly in domestic and overseas markets, with significant demand for optical modules [5][6]. Market Performance - The company's stock has shown a positive trend, with a notable increase in performance over the past year, reflecting strong market confidence [7].

证券研究报告 | 2025年05月26日 长青集团（002616.SZ） 优于大市 行稳致远的生物质发电龙头，携手中科系推动数字+智能转型 公司为民营生物质发电龙头企业。公司 1993 年成立，以燃气具制造业务起 家，2004 进入垃圾焚烧发电领域，2007 年进入农林生物质发电领域。2021 年公司剥离制造业务成为 A 股市场上独树一帜的以农林生物质资源化利用 为主攻方向的上市公司。截至 2024 年末，公司农林生物质发电项目业务总 装机容量 491MW，仅次于国能生物和光大绿色环保位居行业第三。 生物质发电行业：经营状况承压，补贴欠款问题亟待解决。截至 2024 年底， 全国生物质发电装机容量达到 4599 万千瓦，新增装机 185 万千瓦。但 包括南网能源、华能国际、九洲集团在内的多家上市公司均对生物质发 电资产计提了资产减值损失，我们认为这与电价补贴拖欠和原材料价格 上涨等因素有关，但长青集团却依靠精细化管理业绩实现逆势增长。 核心竞争优势：风险管控+经营效益。风险管控优势：公司从项目选址到客 户选择再到产品布局均有考量，紧密跟踪《可再生能源电价附加补助资金 管理办法》修订动态，13 个项目成功纳入国 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - In 2024, the company achieved operating revenue of 4.237 billion yuan, a year-on-year decrease of 5.69%, and a net profit attributable to the parent company of 110 million yuan, a year-on-year decrease of 62.63% [2][4] - In Q4 2024, the company reported operating revenue of 1.192 billion yuan, a year-on-year increase of 6.86%, while the net profit attributable to the parent company was 16 million yuan, a year-on-year decrease of 86.33% [2][4] - In Q1 2025, the company achieved operating revenue of 1.085 billion yuan, a year-on-year increase of 5.19%, and a net profit attributable to the parent company of 42 million yuan, a year-on-year increase of 4.67% [2][4] Summary by Sections Financial Performance - The company experienced a strategic adjustment in its brand portfolio in 2024, leading to revenue pressure and a decline in profit margins. However, the gross margin improved by 4.6 percentage points due to an ongoing optimization of brand structure, with a higher proportion of high-end brands [11] - The sales expense ratio increased by 7.7 percentage points year-on-year, attributed to increased brand promotion investments, while the management and R&D expense ratios also saw slight increases [11] - In Q4 2024, the company saw a recovery in revenue growth, with a year-on-year increase of 7%, and a gross margin improvement of 3.1 percentage points [11] - For Q1 2025, the company maintained stable revenue growth of 5%, with a gross margin increase of 2.4 percentage points, indicating effective control over brand marketing expenses [11] Future Outlook - The company aims to establish itself as a "global emerging luxury beauty group," with ongoing investments in high-end brands and market expenses. The revenue is expected to stabilize, and profit margins are anticipated to gradually recover [11] - Forecasted net profits for 2025, 2026, and 2027 are projected to be 230 million yuan, 320 million yuan, and 390 million yuan, respectively [11]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - In 2024, the company achieved a total revenue of 10.78 billion, representing a year-on-year growth of 21%, and a net profit attributable to shareholders of 1.55 billion, up 30% year-on-year. In Q4 2024, the revenue was 3.81 billion, with a growth of 4.3%, and the net profit was 550 million, growing by 23.4% year-on-year. For Q1 2025, the revenue reached 2.36 billion, a growth of 8.1%, with a net profit of 390 million, up 28.9% year-on-year [2][4]. Summary by Sections Revenue and Profit Performance - In 2024, the main brand maintained steady growth, with online and offline revenues of 10.23 billion and 530 million respectively, showing a growth of 23.7% and a decline of 13.6%. The main brand generated 8.58 billion in revenue, up 19.6% year-on-year. The company launched new products and upgraded core series during the reporting period [5][6]. Margin and Cost Management - The company's net profit margin improved by 1.0 percentage points in 2024, primarily due to a 1.5 percentage point increase in gross margin to 71.4%, attributed to lower freight rates. The sales expense ratio increased by 3.3 percentage points due to higher promotional costs, while management expenses decreased by 1.7 percentage points due to reduced share-based payment costs [6][7]. Future Growth Potential - In Q1 2025, the company demonstrated strong profit elasticity with a net profit margin increase of 2.7 percentage points to 16.5%. The gross margin rose by 2.7 percentage points to 72.8%, likely due to a decrease in major raw material costs. The company expects continued growth from its sub-brands and core series upgrades, which are anticipated to contribute to future revenue growth [7][8]. Earnings Forecast - The company forecasts EPS of 4.63, 5.40, and 6.02 yuan per share for 2025, 2026, and 2027 respectively, indicating a positive outlook for earnings growth [7].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 38.64 CNY based on a 46x PE for 2025 [2][5]. Core Views - The company experienced a significant decline in profits in 2024, with a net profit of 0.42 billion CNY, down 71.9% year-on-year, primarily due to goodwill impairment. However, the first quarter of 2025 shows signs of recovery, with a net profit of 0.44 billion CNY, up 6.8% year-on-year [10]. - The company's existing business faced challenges, but growth opportunities are emerging as marketing transformations progress. The sales revenue for the product "Su Ling" was 5.92 billion CNY, down 3.5% year-on-year, while "Mi Ge Xi" saw a revenue drop of 21.6% due to local procurement policies [10]. - The clinical pipeline is advancing well, with several key products in development, including KC1036 for esophageal squamous cell carcinoma, which has shown promising results in clinical trials [10]. Financial Summary - The company's revenue for 2023 was 9.20 billion CNY, with a projected decline to 8.25 billion CNY in 2024, followed by a recovery to 9.69 billion CNY in 2025, representing a 17.4% growth [4]. - The net profit for 2023 was 1.50 billion CNY, expected to drop to 0.42 billion CNY in 2024, but forecasted to rebound to 1.33 billion CNY in 2025, reflecting a 215.6% increase [4]. - The earnings per share (EPS) are projected to be 0.84 CNY in 2025, increasing to 1.14 CNY in 2026 and 1.40 CNY in 2027 [2][4].

公司研究 证 券 研 究 报 告 南网科技（688248）2024 年报及 2025 年一季报点评 强推（维持） "技术服务+智能设备"双轮驱动，成长可期 事项： 公司发布 2024 年报及 2025 年一季报。2024 年实现营业收入 30.1 亿元，同比 +18.8%；归母净利润为 3.7 亿元，同比+29.8%；扣非净利润为 3.5 亿元，同比 +30.6%。2025Q1 实现营业收入 5.1 亿元，同比+0.9%；归母净利润为 0.6 亿元， 同比+35.7%；扣非净利润为 0.6 亿元，同比+47.1%。 评论： 风险提示：电网投资不及预期；储能业务进展不及预期；行业竞争加剧等。 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 3,014 | 4,126 | 5,433 | 7,104 | | 同比增速(%) | 18.8% | 36.9% | 31.7% | 30.8% | | 归母净利润(百万) | 365 | 481 | ...

证券研究报告 | 2025年05月26日 长青集团（002616.SZ） 优于大市 行稳致远的生物质发电龙头，携手中科系推动数字+智能转型 公司为民营生物质发电龙头企业。公司 1993 年成立，以燃气具制造业务起 家，2004 进入垃圾焚烧发电领域，2007 年进入农林生物质发电领域。2021 年公司剥离制造业务成为 A 股市场上独树一帜的以农林生物质资源化利用 为主攻方向的上市公司。截至 2024 年末，公司农林生物质发电项目业务总 装机容量 491MW，仅次于国能生物和光大绿色环保位居行业第三。 生物质发电行业：经营状况承压，补贴欠款问题亟待解决。截至 2024 年底， 全国生物质发电装机容量达到 4599 万千瓦，新增装机 185 万千瓦。但 包括南网能源、华能国际、九洲集团在内的多家上市公司均对生物质发 电资产计提了资产减值损失，我们认为这与电价补贴拖欠和原材料价格 上涨等因素有关，但长青集团却依靠精细化管理业绩实现逆势增长。 核心竞争优势：风险管控+经营效益。风险管控优势：公司从项目选址到客 户选择再到产品布局均有考量，紧密跟踪《可再生能源电价附加补助资金 管理办法》修订动态，13 个项目成功纳入国 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 1,900.00 CNY, representing a potential upside of 20.8% from the current price of 1,572.60 CNY [6][7][8]. Core Insights - The company is undergoing a strategic transformation focusing on cultural heritage and market adaptation to changing consumer scenarios, aiming to enhance its brand value and pricing power in the high-end liquor market [8]. - The management has emphasized maintaining quality and brand strength while expanding into new consumption scenarios, such as family gatherings and personal milestones, indicating a shift from product-centric to lifestyle-oriented value creation [8]. - The company is expected to achieve significant revenue growth, with projected total revenues increasing from 150.56 billion CNY in 2023 to 223.57 billion CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 8.0% [5][9]. - Net profit is forecasted to grow from 74.73 billion CNY in 2023 to 112.69 billion CNY in 2027, with a similar CAGR of around 8.8% [5][9]. Financial Summary - Total revenue for 2023 is reported at 150.56 billion CNY, with a year-on-year growth of 19.0%, and is expected to reach 174.14 billion CNY in 2024, a growth of 15.7% [5][9]. - The net profit for 2023 stands at 74.73 billion CNY, with a growth rate of 19.2%, projected to increase to 86.23 billion CNY in 2024, reflecting a growth of 15.4% [5][9]. - The basic earnings per share (EPS) is expected to rise from 59.49 CNY in 2023 to 89.71 CNY by 2027, indicating a steady increase in shareholder value [5][9]. Strategic Focus - The company is implementing a three-phase strategy focusing on internationalization and youth engagement, aiming to create new growth drivers [8]. - Short-term strategies include optimizing customer structure and expanding consumption scenarios, while mid-term strategies focus on cultural export and international value creation [8]. - Long-term goals involve building a resilient business ecosystem that enhances risk management and stakeholder value [8].